Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Fang Douglas Dong"'
Autor:
Fang Douglas Dong, Jing Deng, Tingting Mao, Jinlan Pan, Xiaolan Shi, Jingjing Shang, Lingzhi Yan, Shuang Yan, Yingying Zhai, Yifan Zhai, Jing Wang, Chengcheng Fu, Depei Wu, Yan Xie, Song Jin, Yan Yin, Ying Yao, Panfeng Wang, Dajun Yang
Publikováno v:
Blood. 136:46-47
Background Multiple myeloma (MM) is a heterogenous plasma cell malignancy. About 30-40% of newly diagnosed and 20-60% of relapsed/refractory MM patients carry 1q21 amplification worldwide, a high-risk indicator for poor prognosis in RRMM. Different B
Autor:
Fang Douglas Dong, Xiaojing Huang, Yifan Zhai, Guangfeng Wang, Dajun Yang, Tingting Mao, Jing Deng, Li Rui
Publikováno v:
Blood. 134:2573-2573
Introduction Ibrutinib, a first-in-class oral covalent inhibitor of Bruton's tyrosine kinase (BTK), has been FDA-approved for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia (CLL) and Waldenström's macroglobulinemia. In CLL, 80%
Autor:
Fang Douglas Dong, Guoqin Zhai, Tingting Mao, Jing Deng, Shaomeng Wang, Dongmei Yang, Yan Yin, Yang Dajun, Yifan Zhai
Publikováno v:
Blood. 132:2616-2616
Introduction Evading apoptosis is one of the key mechanisms that cells become cancerous. Oncogenic proteins in the family, including BCL-2, BCL-xL, and MCL-1, which counteract the pro-death function of tumor suppressor like proteins, have been shown